Ensysce Biosciences (ENSC) said Monday it has regained compliance with Nasdaq's minimum stock price requirement for continued listing.
The pharmaceutical company said that since it had earlier regained compliance the exchange's stockholders' equity rule, it has now met all requirements outlined in a recent hearings panel decision, so its stock will continue trading on the Nasdaq Capital Market.
Price: 8.29, Change: +0.19, Percent Change: +2.35